NCT05933213View on ClinicalTrials.gov

Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Lupus Nephritis
Interventions
DRUG

Mescaline sodium enteric-coated tablets

Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d

DRUG

Morte-mescaline

Induction period: orally, twice a day, 1-2 g/d; Maintenance period: orally, twice a day, 0.5-0.75 g/d

DRUG

Glucocorticoids

glucocorticoids

All Listed Sponsors
collaborator

Beijing Medical Award Foundation

UNKNOWN

lead

Xiangya Hospital of Central South University

OTHER

NCT05933213 - Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis | Biotech Hunter | Biotech Hunter